News - Biogen Idec, daclizumab


Current filters:

Biogen Idecdaclizumab

Popular Filters

New entrants to multiple sclerosis market will drive 10% pa growth through 2018


The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10%…

AbbVieAubagioBayerBiogen IdecBiotechnologydaclizumabGlobalLemtradaMarkets & MarketingNeurologicalocrelizumabPharmaceuticalRocheSanofiTecfidera

Biogen jumps on strong MS drug data: Sanofi’s Lemtrada significant improvement on Rebif


US biotech firm Biogen Idec (Nasdaq: BIIB) saw its shares jump 6% to $107.53 last Friday, after the company…

AlemtuzumabBiogen IdecBiotechnologydaclizumabdimethyl fumarateGenzymeLemtradaNeurologicalPharmaceuticalResearchSanofi

Biogen Idec and Abbott MS drug candidate daclizumab positive in Ph IIb


US biotech Biogen Idec (Nasdaq: BIIB) and health care giant Abbott Laboratories (NYSE: ABT ) have announced…

Abbott LaboratoriesBiogen IdecBiotechnologydaclizumabNeurologicalPharmaceuticalResearch

Back to top